Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have earned an average recommendation of “Moderate Buy” from the ten research firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $19.00.

Several equities analysts recently issued reports on FULC shares. HC Wainwright upped their target price on Fulcrum Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, December 8th. JPMorgan Chase & Co. initiated coverage on Fulcrum Therapeutics in a research note on Monday, January 12th. They set an “overweight” rating and a $20.00 price target on the stock. Leerink Partners reissued an “outperform” rating on shares of Fulcrum Therapeutics in a report on Tuesday, February 24th. Stifel Nicolaus set a $25.00 price objective on Fulcrum Therapeutics in a research note on Monday, December 8th. Finally, Wall Street Zen downgraded Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 17th.

Fulcrum Therapeutics Trading Down 2.8%

NASDAQ:FULC opened at $7.94 on Tuesday. Fulcrum Therapeutics has a twelve month low of $2.32 and a twelve month high of $15.74. The company has a market cap of $528.80 million, a PE ratio of -6.73 and a beta of 3.23. The company’s 50 day moving average is $10.11 and its two-hundred day moving average is $9.58.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.31). As a group, analysts expect that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Insider Transactions at Fulcrum Therapeutics

In other Fulcrum Therapeutics news, Director Robert J. Gould sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total transaction of $178,050.00. Following the completion of the transaction, the director directly owned 469,864 shares of the company’s stock, valued at approximately $5,577,285.68. This trade represents a 3.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of Fulcrum Therapeutics

Large investors have recently made changes to their positions in the business. Aberdeen Group plc boosted its stake in shares of Fulcrum Therapeutics by 135.0% in the third quarter. Aberdeen Group plc now owns 137,961 shares of the company’s stock worth $1,269,000 after buying an additional 79,265 shares during the last quarter. Acadian Asset Management LLC raised its position in Fulcrum Therapeutics by 63.5% during the second quarter. Acadian Asset Management LLC now owns 563,380 shares of the company’s stock valued at $3,871,000 after acquiring an additional 218,819 shares in the last quarter. Bailard Inc. acquired a new position in Fulcrum Therapeutics in the second quarter valued at approximately $185,000. Campbell & CO Investment Adviser LLC acquired a new position in Fulcrum Therapeutics in the third quarter valued at approximately $943,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Fulcrum Therapeutics by 57.3% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,547 shares of the company’s stock worth $2,357,000 after purchasing an additional 124,798 shares in the last quarter. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.